Knights of Columbus Asset Advisors LLC Buys 2,116 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Knights of Columbus Asset Advisors LLC grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 82.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,695 shares of the biopharmaceutical company’s stock after buying an additional 2,116 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $1,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new stake in Madrigal Pharmaceuticals in the fourth quarter worth $70,000. Quest Partners LLC increased its position in Madrigal Pharmaceuticals by 172.8% in the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 368 shares during the last quarter. KBC Group NV increased its position in Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 258 shares during the last quarter. Miracle Mile Advisors LLC bought a new position in Madrigal Pharmaceuticals during the fourth quarter valued at $216,000. Finally, D.A. Davidson & CO. bought a new position in Madrigal Pharmaceuticals during the fourth quarter valued at $221,000. Institutional investors own 98.50% of the company’s stock.

Insider Activity

In other news, VP Robert E. Waltermire sold 442 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $273.41, for a total transaction of $120,847.22. Following the transaction, the vice president now owns 5,058 shares in the company, valued at $1,382,907.78. This represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Carole Huntsman sold 347 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $116,328.28. Following the transaction, the insider now owns 10,438 shares in the company, valued at approximately $3,499,235.12. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,900 shares of company stock worth $12,168,079 over the last 90 days. 22.80% of the stock is currently owned by corporate insiders.

Madrigal Pharmaceuticals Stock Up 1.9 %

NASDAQ:MDGL opened at $341.62 on Friday. The firm has a market cap of $7.54 billion, a PE ratio of -13.62 and a beta of -0.40. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The company has a 50-day moving average of $327.53 and a 200 day moving average of $293.77. Madrigal Pharmaceuticals, Inc. has a 1-year low of $189.00 and a 1-year high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, topping analysts’ consensus estimates of ($4.32) by $1.61. The firm had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million. As a group, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MDGL. HC Wainwright boosted their price objective on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Citigroup boosted their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, B. Riley raised shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and upped their price objective for the stock from $236.00 to $422.00 in a research note on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $378.44.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.